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Peripheral nerve field stimulation for
trigeminal neuralgia, trigeminal
neuropathic pain, and persistent
idiopathic facial pain
Johann Klein, Sahr Sandi-Gahun, Gabriele Schackert and
Tareq A Juratli
Abstract
Objective: Peripheral nerve field stimulation (PNFS) is a promising modality for treatment of intractable facial pain.
However, evidence is sparse. We are therefore presenting our experience with this technique in a small patient cohort.
Methods: Records of 10 patients (five men, five women) with intractable facial pain who underwent implantation of one
or several subcutaneous electrodes for trigeminal nerve field stimulation were retrospectively analyzed. Patients’ data,
including pain location, etiology, duration, previous treatments, long-term effects and complications, were evaluated.
Results: Four patients suffered from recurrent classical trigeminal neuralgia, one had classical trigeminal neuralgia
and was medically unfit for microvascular decompression. Two patients suffered from trigeminal neuropathy attributed
to multiple sclerosis, one from post-herpetic neuropathy, one from trigeminal neuropathy following radiation therapy
and one from persistent idiopathic facial pain. Average patient age was 74.2 years (range 57–87), and average symptom
duration was 10.6 years (range 2–17). Eight patients proceeded to implantation after successful trial. Average follow-up
after implantation was 11.3 months (range 5–28). Using the visual analog scale, average pain intensity was 9.3 (range
7–10) preoperatively and 0.75 (range 0–3) postoperatively. Six patients reported absence of pain with stimulation; two
had only slight constant pain without attacks.
Conclusion: PNFS may be an effective treatment for refractory facial pain and yields high patient satisfaction.
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Introduction
In recent years, peripheral nerve field stimulation
(PNFS) has been gathering a growing body of evidence
as a treatment option for patients with chronic pain
syndromes refractory to conventional therapy forms.
This surgical approach denotes the subcutaneous inser-
tion of one or several electrodes in the painful area and
subsequent electrical stimulation. In analogy to spinal
cord stimulation or direct peripheral nerve stimulation,
a trial, usually lasting several days to several weeks, is
performed and the definite system is implanted after-
wards in the case of a successful trial period.
Most notably, occipital nerve stimulation, some-
times in combination with subcutaneous electrode
placement in the supraorbital, temporal or frontal
region, has been increasingly and successfully used in
patients with migraine, cluster headache or other pri-
mary headache syndromes (1–6). Furthermore, the use
of PNFS in the treatment of low back pain has been
established through several prospective studies (7–9).
Other indications under which patients have benefited
from this minimally invasive procedure include inguinal
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post-herniorrhaphy neuropathy, abdominal pain, post-
thoracotomy syndrome, and hip pain (10–13).
For patients with facial pain who have either experi-
enced a relapse after microvascular decompression
(MVD) for classical trigeminal neuralgia or suffer
from a pain syndrome not amenable to MVD, further
options are called for. Therapies in question include
radiofrequency rhizotomy or radiosurgery. Being
destructive procedures that can cause irreversible
facial numbness as a side effect, they may be regarded
as options of last resort in the era of neuromodulation.
A thorough review of diagnostic and therapeutic
options in trigeminal neuralgia has been provided else-
where (14).
There is an increasing number of reports dealing
with PNFS in patients suffering from facial pain. For
the most part, painful trigeminal neuropathy following
craniofacial surgery or trauma as well as post-herpetic
trigeminal neuropathy have been identified as indica-
tions well amenable to this neuromodulatory interven-
tion when more established therapies have failed
(15–18). Evidence, however, does not exceed case
reports or small patient series (Table 1). Moreover,
experience with stimulation for classical trigeminal
neuralgia has rarely been reported at all. Here, we pre-
sent a retrospective analysis of patients who have
received PNFS for different kinds of facial pain.
Methods
Patient population
Between August 2012 and December 2014, 10 patients
in our institution had PNFS electrodes inserted for trial
because of intractable facial pain. Five were male and
five female, the mean patient age was 74.2 years (range
57–87 years). All had facial pain in any one or two of
the innervation areas of the trigeminal nerve, although
in some cases an exact anatomical attribution was dif-
ficult. Mean symptom duration was 10.6 years (range
2–17 years); all participants had undergone complex
medical, interventional and/or surgical therapies
before. A positive trial was considered if the patients
experienced a 50% decrease of pain on the visual
analog scale. As facial pain syndromes are often diffi-
cult to distinguish from one another and referring phys-
icians may lack experience with more specific etiologies,
the reported diagnoses were reviewed and in some cases
corrected after thorough study of the individual
patient’s medical history, interview and neurologic
examination. One patient had a post-herpetic trigem-
inal neuropathy; another had a painful post-traumatic
trigeminal neuropathy following radiation treatment
for mucosa-associated lymphoid tissue (MALT) lymph-
oma. Two patients suffered from painful trigeminal
neuropathy attributed to multiple sclerosis, five had
classical trigeminal neuralgia, and one had a pain syn-
drome without any neuropathic quality that was diffi-
cult to categorize and most likely conformed to
persistent idiopathic facial pain (PIFP). Four of the
five patients with classical trigeminal neuralgia had
undergone microvascular decompression surgery at
least once before but experienced no lasting improve-
ment. In one patient, microvascular decompression had
initially been scheduled but was finally advised against
in favor of PNFS because the patient suffered from
meningitis before the surgery could be performed.
Eight patients reported to have a positive trial and
therefore proceeded with system implantation.
Patients’ characteristics and pain parameters are sum-
marized in Table 2.
All patients filled out an extensive questionnaire
upon their first presentation to our outpatient depart-
ment, including exact description of localization, inten-
sity and quality of their pain as well as the resulting
limitations in activities of daily living. A rating scale for
evaluation of pain intensity ranging from 0 (no pain) to
10 (maximum pain) was part of the questionnaire.
Trial stimulation
On the day before surgery, the patients were asked to
exactly mark the painful facial area (Figure 1).
Electrode placement was performed after sterile prep-
aration and draping either in local or in general anes-
thesia, depending on patient choice and estimated
compliance during the operation. Cefuroxime in the
amount of 1.5 g was applied as a single shot antibiotic.
A pre-auricular 1 cm–1.5 cm skin incision was made just
behind the hairline above the zygomatic arch and an
electrode (Pisces Quad Plus, Medtronic, Minneapolis,
MN, USA) was placed subcutaneously from lateral to
medial via a 15-Ga Tuohy needle into the center of the
previously identified painful region (Figure 1). In
patients with larger algesic areas, we preferred to
insert two electrodes. If the patient was awake, a test
stimulation was conducted to confirm the correct pos-
itioning of the electrode by covering the pain area with
paresthesia. The lead was then fixated to the fascia with
an anchor and connected to an extension cable that was
passed to the retroauricular area and externalized. A
loop allowed for redundancy of the cable in order to
avoid dislocation of the lead. Following implantation,
programming took place on the same day and the
patients were trained in handling and adjusting the
stimulation voltage. On day eight, the externalized
cable was capped in our outpatient department. In
three patients, the electrode was not connected to an
extension cable during implantation but sutured to the
skin. In these cases, the electrode was removed on day
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Table 1. Literature review of PNFS for facial pain.
Authors and year
Number
of patients
Age (years),
sex Etiology Area Implant FU Outcome Complications
Dunteman, 2002 (19) 2 86, M PH Lt V1 SON 3 yrs Improved
76, F PH Lt V1 SON 3 yrs Improved
Johnson and Burchiel,
2004 (20)
10 39, F PT Rt V1 SON 2 yrs 70% of pts with Wound breakdown
86, M PH Rt V1 SON 2 yrs >50% pain relief None
44, M PH Rt V1 SON 2 yrs None
37, F AFP Lt V1 SON 2 yrs Wound breakdown
61, M PH Lt V1 SON 2 yrs Short extension cable
41, M PT Rt V1 SON 2 yrs None
83, F PH Lt V1 SON 2 yrs None
53, M PT Lt V1 SON 2 yrs None
45, M PT Lt V1 ION 2 yrs None
33, M PT Rt V1 ION 2 yrs None
Slavin et al., 2006a (15) 9 SON (4); ION (3); 35 mos 73% of pts with
IONþON (1); >50% pain relief
SONþON (1)
Narouze and Kapural,
2007 (21)
1 35, M CH Rt V1 SON 14 mos Remission None
Asensio-Samper et al.,
2008 (22)
1 34, M PT Re V1 SON 4 yrs VAS score from 10 to 2
Amin et al., 2008 (23) 10 35, M SN V1 SON 30 wks VAS score from
7.5 to 3.5 (average)
Superficial infection
in 20%, skin
erosion, breakdown
of the postauricular
anchoring site
39, M SN V1 SON 30 wks
36, F SN V1 SON 30 wks
46, F SN V1 SON 30 wks
40, F SN V1 SON 30 wks
46, F SN V1 SON 30 wks
46, F SN V1 SON 30 wks
33, M SN V1 SON 30 wks
56, M SN V1 SON 30 wks
53, F SN V1 SON 30 wks
Reverberi et al., 2009 (24) 1 61, F ETN Rt V1, V2 SONþ ION 5 mos VAS score from 10 to 1 Electrode dislocation
Surjya Prasad Upadhyay
et al., 2010 (25)
1 PH V1 SON 8 wks Excellent None
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Table 1. Continued.
Authors and year
Number
of patients
Age (years),
sex Etiology Area Implant FU Outcome Complications
Yakovlev and Resch, 2010 (26) 1 72, F AFP Lt V3 MN 12 mos Excellent
Stidd et al., 2012 (17) 3 71, M PT Lt V1, V2 SONþ ION 27 mos VAS score from 10 to 0 Occasional HA
52, M PT Lt V1, V2 SONþ ION 23 mos VAS score from 8 to 0
44, M PH Rt V1 SON (2 electrodes) 6 mos 60% pain relief Electrode dislocation
Lenchig et al., 2012 (16) 1 42, F PS Rt V1, V2 SONþ ION 3 mos >50% pain relief None
Feletti et al., 2013 (18) 6 22, F PIFP Lt V1, V2, ON SON, ION, ON 15 mos VAS score from 10 to 2 None
58, M PT Rt V1, ON ON 32 mos VAS score from 9 to 4 None
41, F PT Lt> rt V2, V3 ION 19 mos VAS score from 10 to Traumatic rupture
0 (lt), 5 (rt)
54, F PS (chemical) Lt V1, V2, V3 ON, ION, MN 12 mos VAS score from 10 to 2 Infection
77, F PH Rt V1 SON 24 mos VAS score from 10 to 3 None
67, F PIPF Rt V2 ION 3 wks VAS score from 10 to 3 None
Verrills et al., 2014a (6) 10 SONþ ION (3); 12.9 mos 68% of pts with
combination of (average) >50% pain relief
ON, SON, ION (7)
Ellis et al., 2015 (27) 15 15 mos
(average)
73% of pts with
improvement
Modified after Feletti et al. (18).
AFP: atypical facial pain; CH: cluster headache; ETN: essential trigeminal neuralgia; F: female; FU: follow-up; HA: headache; ION: infraorbital nerve; Lt: left; M: male; MN: mandibular nerve; mos: months; ON:
occipital nerve; PH: post-herpetic; PIFP: persistent idiopathic facial pain; PNFS: peripheral nerve field stimulation; PS: postsurgical; PT: post-traumatic; pts: patients; Rt: right; SON: supraorbital nerve, wks:
weeks; VAS: visual analog scale; yrs: years.
aData are the mean values referring to a wider series including occipital nerve stimulation.
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eight and had to be replaced upon implantation of the
definite stimulation system.
Implantation
After a positive trial period, the implantation of the
permanent system was performed in a second proced-
ure under general anesthesia. Cefuroxime in the
amount of 1.5 g was administered and after routine
preparation and draping, either the preauricular inci-
sion was reopened to implant a new electrode or both
the pre- and retroauricular incisions were reopened to
replace the extension cable. In either case, the electrode
was passed to the retroauricular area where it was con-
nected to a (new) extension cable. A subcutaneous
pocket for the implantable pulse generator (IPG) was
created either in the abdominal or the chest wall. After
tunneling, the extension cable was connected to the IPG
(PrimeAdvanced, Medtronic, Minneapolis, MN, USA),
which was then inserted and fixated to the fascia with
non-absorbable sutures. After an impedance check,
assurance of hemostasis and irrigation of the pocket
with gentamicin solution, the wounds were closed.
We didn’t use intraoperative fluoroscopy. However, a
postoperative X-ray was performed in all patients
for documentation of correct implantation (Figure 2).
Stimulation began on the day after surgery and the
patients were discharged on day three after having
been trained in handling the programming device.
Stimulation settings
Stimulation settings were determined for each patient
individually with regard to best effect and avoidance of
side effects. Our aim was to induce slight but persistent
paresthesia. Depending on the patient’s pain character-
istics, some were trained in reducing stimulation inten-
sity to achieve subthreshold stimulation during pain-
free intervals. However, the patients were advised not
to completely turn off the stimulation, even when they
were pain free. Usually, a frequency of 60–80 Hz and
impulse duration of 450 m were chosen. All four con-
tacts were activated in the order anode-cathode-anode-
cathode.
Follow-up and outcome analysis
The patients returned to our outpatient department 10
days after implantation for suture removal, wound
examination and evaluation of the therapeutic effect.
If necessary, stimulation parameters were adjusted
and handling of the programming device was again
explained to the patients and their relatives. In add-
ition, all patients were routinely evaluated twice a
year in our outpatient department.T
a
b
le
2
.
C
h
ar
ac
te
ri
st
ic
s
o
f
p
at
ie
n
ts
tr
ea
te
d
w
it
h
P
N
FS
fo
r
fa
ci
al
p
ai
n
at
o
u
r
in
st
it
u
ti
o
n
.
A
ge
(y
ea
rs
),
se
x
E
ti
o
lo
gy
M
V
D
A
re
a
Im
p
la
n
t
FU (m
o
s)
V
A
S
sc
o
re
p
re
o
p
V
A
S
sc
o
re
p
o
st
o
p
A
n
al
ge
si
cs
p
re
o
p
A
n
al
ge
si
cs
at
la
te
st
FU
C
o
m
p
lic
at
io
n
s
7
2
,
M
C
T
N
Y
es
R
t
V
2
IO
N
2
8
1
0
0
C
B
Z
N
o
n
e
E
le
ct
ro
d
e
d
ef
ec
t
7
8
,
M
C
T
N
Y
es
R
t
V
1
,
V
2
SO
N
þ
IO
N
2
0
1
0
0
P
G
B
,
O
X
C
,
B
A
C
P
G
B
,
O
X
C
,
B
A
C
W
o
u
n
d
b
re
ak
d
o
w
n
7
5
,
M
M
S
N
o
L
t
V
3
M
N
1
2
9
0
P
H
T
,
C
B
Z
,
B
A
C
,
H
Y
D
N
o
n
e
N
o
n
e
7
6
,
M
M
S
N
o
L
t
V
2
,
V
3
IO
N
þ
M
N
8
1
0
0
G
B
P,
O
X
C
,
A
ct
G
B
P,
O
X
C
N
o
n
e
8
7
,
F
C
T
N
Y
es
R
t
V
1
,
V
2
SO
N
þ
IO
N
5
1
0
0
G
B
P,
A
ct
,
O
X
C
,
B
A
C
O
X
C
N
o
n
e
5
7
,
F
C
T
N
N
o
R
t
V
2
IO
N
5
1
0
3
G
B
P,
LT
G
,
P
H
T
,
T
R
A
,
A
ct
,
B
A
C
G
B
P,
LT
G
,
P
H
T
,
T
R
A
,
B
A
C
IP
G
d
is
lo
ca
ti
o
n
a
7
6
,
F
C
T
N
Y
es
R
t
V
2
,
V
3
IO
N
þ
M
N
7
.5
8
.5
0
P
G
B
,
T
R
A
P
G
B
,
T
R
A
N
o
n
e
7
3
,
F
P
IF
P
N
o
R
t
V
2
IO
N
5
7
3
G
B
P,
C
B
Z
G
B
P,
C
B
Z
N
o
n
e
a
N
o
re
vi
si
o
n
su
rg
er
y
p
er
fo
rm
ed
.
A
ct
:
ac
et
am
in
o
p
h
en
;
B
A
C
:
b
ac
lo
fe
n
;
C
B
Z
:
ca
rb
am
az
ep
in
e;
FU
:
fo
llo
w
-u
p
;
G
B
P
:
ga
b
ap
en
ti
n
;
H
Y
D
:
hy
d
ro
m
o
rp
h
o
n
e;
IO
N
:
in
fr
ao
rb
it
al
n
er
ve
;
IP
G
:
im
p
la
n
ta
b
le
p
u
ls
e
ge
n
e
ra
to
r;
L
t:
le
ft
;
LT
G
:
la
m
o
tr
ig
in
e
;
M
N
:
m
an
d
ib
u
la
r
n
er
ve
;
m
o
s:
m
o
n
th
s;
O
X
C
:
o
x
ca
rb
az
ep
in
e;
P
H
T
:
p
h
en
yt
o
in
;
P
IF
P
:
p
er
si
st
en
t
id
io
p
at
h
ic
fa
ci
al
p
ai
n
;
P
N
FS
:
p
er
ip
h
er
al
n
er
ve
fie
ld
st
im
u
la
ti
o
n
;
SO
N
:
su
p
ra
o
rb
it
al
n
e
rv
e
;
T
R
A
:
tr
am
ad
o
l;
V
A
S:
vi
su
al
an
al
o
g
sc
al
e;
yr
s:
ye
ar
s.
Klein et al. 449
Figure 1. Implantation of two electrodes for trial stimulation in the right ION and MN areas. (a) The painful area and the planned
trajectories of the electrodes have been delineated preoperatively. The hairline has been marked and a small area shaved. (b) A 1 cm–
1.5 cm incision is made and dissection is performed to visualize the fascia. (c) A 15-Ga Tuohy needle is inserted subcutaneously to
allow for advancement of the electrode. (d) Both electrodes are externalized and sutured to the skin. The crosses beneath the ala of
the nose and the lower lip mark the tips of the electrodes.
ION: infraorbital nerve; lt ¼ left; MN: mandibular nerve.
Figure 2. Postoperative radiograph in a patient after definite implantation of two PFNS electrodes in the left ION and MN areas.
PNFS: peripheral nerve field stimulation; ION: infraorbital nerve; MN: mandibular nerve.
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The follow-up was complemented by telephone
interviews about current maximum pain intensity on
the numeric rating scale, complications, side effects,
and changes in medication. All patients signed a written
informed consent form for publication of their data.
The stated maximum pain intensity was then compared
to the preoperative value.
Results
In eight patients, 12 permanent electrodes and eight
generators were implanted (four patients had one and
four had two electrodes). Average follow-up time was
11.3 months after the implant (range 5–28 months) with
no patient lost. Two more patients underwent trial
stimulation: An 85-year-old man with post-herpetic tri-
geminal neuralgia stated contradictory effects, thus the
trial was regarded as negative. A 64-year-old woman
with painful trigeminal neuropathy following radiation
treatment for MALT lymphoma showed no marked
improvement upon trial stimulation.
In our series, all patients with permanent elec-
trode implantation experienced a lasting and signifi-
cant pain reduction. The mean pain intensity during
the most intense intervals, such as during a pain
attack or with constant pain when attacks were
absent, was 0.75 (range 0–3), compared to 9.3
before electrode implantation. Six patients (75%)
were completely pain free at the time of latest
follow-up. Five patients were able to reduce medica-
tion; two of them no longer took any analgesics
(Table 2). Of the two patients who were not pain
free, both stated a maximum pain intensity of 3 at
the latest follow-up. One never had attacks but a
PIFP with constant pain, and the other had a clas-
sical trigeminal neuralgia with constant background
pain that did not vanish completely; however, no
attacks occurred anymore as compared to several
attacks per week preoperatively.
Two patients required revision surgery because of
minor complications. In one, an electrode had to be
replaced a year and a half after implantation because
of an electrode defect. Another had a minor wound
healing deficiency that necessitated debridement four
months after implantation. No hardware removal
had to be performed. In one patient, a dislocation
of the IPG in the abdominal wall arose, probably
because of insufficient fixation during its implant-
ation. However, function was uncompromised and
the patient decided against a revision. We observed
no infections or other serious complications.
Stimulation-dependent side effects were virtually
absent: One patient reported hypoesthesia of the
scalp on the stimulated side and one has noticed a
sensitivity to weather changes with slight dull
sensations on the stimulated side that were difficult
to localize but not painful in character.
Discussion
This retrospective analysis of 10 patients with intract-
able facial pain suggests that PNFS could turn out to
be an effective treatment option for refractory trigem-
inal neuropathic pain even in an elderly population
with comorbidities, provided the results can be con-
firmed in randomized controlled trials.
In our series, five individuals suffering from classical
trigeminal neuralgia, along with two patients having
painful trigeminal neuropathy attributed to multiple
sclerosis and one dealing with PIFP, have benefitted
from PNFS. Overall, the outcome was excellent, with
six of the individuals being pain free after implantation
and two showing marked improvement. Some minor
complications arose but none of them were severe.
PNFS has been reported to yield success in facial pain
syndromes before, yet reports remain rare. Slavin and
Wess first described it as trigeminal branch stimulation
(28). Johnson and Burchiel (2004) reported successful
PNFS in 10 patients with trigeminal post-herpetic neur-
algia and posttraumatic neuropathic pain (20). Amin
et al. successfully used the technique in patients with
supraorbital neuralgia (23). Narouze and Kapural
reported on a patient suffering from cluster headache
who benefitted from supraorbital stimulation (21). Out
of two series including patients treated with occipital
nerve stimulation, Slavin et al. reported on nine patients
and Verrills et al. reported on 10 patients, which in both
cases were not elaborated on in terms of etiologies or
patient characteristics (15,6). Recently, Ellis et al.
reported on PNFS testing in 35 patients and definite
implantation in 15 patients with intractable facial pain
(27). The patient population was distinctly different from
ours with a mean age of 53 years and a mean symptom
duration of 5.6 years compared to a mean age of 74
years and a mean symptom duration of 10.6 years in
our study. Furthermore, as in many previous reports,
the electrodes were placed according to anatomical land-
marks. For example, for implantation into the supra-
orbital or infraorbital region, the electrodes were
inserted 1 cm above or below the orbital rim, respect-
ively, while we did not follow anatomical landmarks,
but determined the exact site of implantation according
to the patient’s individual pain distribution. Ellis et al.
(27) report a benefit from trial stimulation in only 49%
of patients, while in our study the response was 80%.
This disparity may have to do with differences in patient
characteristics or be a coincidence. However, a superior
effect of implantation according to pain distribution
rather than according to anatomical landmarks cannot
be excluded.
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Otherwise, only smaller patient groups or single case
reports have been published (16–18,19,22,24–26).
There is no consensus about the optimal implantation
technique and operative setting in PNFS. In both theor-
etical models and clinical findings an implantation depth
of approximately 1 cm below the skin was found to
result in the highest ratio of stimulated Ab- to Ad-
fibers (29,30). A deeper implantation may diminish
stimulation effectivity while a more superficial placement
implicates the risk of burning pain in the affected area.
These data, however, refer to low back tissue and obvi-
ously facial skin rarely provides 1 cm of subcutaneous
tissue. Yet, we have never observed stimulation-induced
burning or other painful sensation in facial PNFS unless
the amplitude was set too high.
In our opinion, trial stimulation is mandatory in
order to select patients most likely to benefit from
this treatment modality. As to local or general anesthe-
sia during implantation of a lead for a stimulation trial,
in our experience, intraoperative testing is not of para-
mount significance. We believe that careful and precise
preoperative delineation of the relevant area is of
higher importance than a subjective description of par-
esthesia during a brief stimulation under—the small
scale of this minor surgical procedure notwithstand-
ing—a stressful and unpleasant situation for the
patient. In the elderly population of our series (only
two patients were younger than 70 years) lack of com-
pliance during electrode placement occasionally
occurred, forcing us to rely on our preoperative mark-
ings. While we have no general objections to local anes-
thesia for such a small procedure even when refraining
from intraoperative testing, we argue that the decision
should be made in accordance with the patient and that
despite the briefness of the surgery, general anesthesia
may be considered for patient comfort.
We didn’t use intraoperative fluoroscopy as,
in our opinion, it doesn’t add to implantation accuracy
when not relying on anatomical landmarks such as the
supraorbital or infraorbital groove. Instead, we prefer to
mark the painful area preoperatively, as described
above.
Our study is limited by its retrospective, observa-
tional nature and the small patient cohort. Important
data, such as activities of daily living and quality of life
estimates, have not been systematically surveyed in the
follow-up period. Prospective studies, especially rando-
mized controlled trials, are needed to more reliably
evaluate the efficacy of PNFS in intractable facial
pain syndromes.
Conclusion
PNFS for chronic refractory trigeminal neuralgia and
trigeminal neuropathy of different etiologies may be an
effective procedure when first-line therapies have failed.
Likewise, a patient with non-neuropathic PIFP showed
significant improvement. Even in a mostly elderly
patient population with long symptom durations, the
response rate was excellent at follow-up times of up to
28 months and no serious complications arose.
Prospective studies, especially randomized controlled
trials, are needed to further evaluate the use of PNFS
in intractable facial pain syndromes.
Clinical implications
. Peripheral nerve field stimulation (PNFS) lowered the average pain intensity in patients suffering from
intractable facial pain from 9.3 to 0.75 on the visual analog scale.
. After a positive trial stimulation, all patients experienced a lasting significant improvement at follow-up
times of up to 28 months.
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